Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
Fiche publication
Date publication
juin 2020
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr REPPEL Loïc
Tous les auteurs :
Fucà G, Reppel L, Landoni E, Savoldo B, Dotti G
Lien Pubmed
Résumé
Chimeric antigen receptor (CAR) T-cell therapy has been acclaimed as a revolution in cancer treatment following the impressive results in hematologic malignancies. Unfortunately, in patients with solid tumors, objectives responses to CAR T cells are still anecdotal, and important issues are driven by on-target but off-tumor activity of CAR T cells and by the extremely complex biology of solid tumors. Here, we will review the recent attempts to challenge the therapeutic impediments to CAR T-cell therapy in solid tumors. We will focus on the most promising strategies of antigen targeting to improve tumor specificity and address the tumor heterogeneity, efforts to circumvent the physical barriers of the tumor architecture such as subverted tumor vasculature, impediments of CAR T-cell trafficking and immune suppressive microenvironment.
Mots clés
Animals, Humans, Immunotherapy, Adoptive, methods, Neoplasms, immunology, Receptors, Antigen, T-Cell, immunology, Tumor Microenvironment, immunology
Référence
Clin Cancer Res. 2020 06 1;26(11):2444-2451